Search

Your search keyword '"Bassand Jean-Pierre"' showing total 231 results
Start Over Author "Bassand Jean-Pierre" Search Limiters Peer Reviewed
231 results on '"Bassand Jean-Pierre"'

2. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)

Author

García Hugo, Bassand Jean-Pierre, Amerena John, Clearfield Michael B, Miller Sam S, Sosef Froukje FM, Palmer Michael K, and Bryzinski Brian S

Subjects
Medicine (General), R5-920
Abstract

Abstract Background Many patients at high risk of cardiovascular disease do not achieve recommended low-density lipoprotein cholesterol (LDL-C) goals. This study compared the efficacy and safety of low doses of rosuvastatin (10 mg) and atorvastatin (20 mg) in high-risk patients with hypercholesterolemia. Methods A total of 996 patients with hypercholesterolemia (LDL-C ≥ 3.4 and < 5.7 mmol/L [130 and 220 mg/dL]) and coronary heart disease (CHD), atherosclerosis, or a CHD-risk equivalent were randomized to once-daily rosuvastatin 10 mg or atorvastatin 20 mg. The primary endpoint was the percentage change from baseline in LDL-C levels at 6 weeks. Secondary endpoints included LDL-C goal achievement (National Cholesterol Education Program Adult Treatment Panel III [NCEP ATP III] goal < 100 mg/dL; 2003 European goal < 2.5 mmol/L for patients with atherosclerotic disease, type 2 diabetes, or at high risk of cardiovascular events, as assessed by a Systematic COronary Risk Evaluation (SCORE) risk ≥ 5% or 3.0 mmol/L for all other patients), changes in other lipids and lipoproteins, cost-effectiveness, and safety. Results Rosuvastatin 10 mg reduced LDL-C levels significantly more than atorvastatin 20 mg at week 6 (44.6% vs. 42.7%, p < 0.05). Significantly more patients achieved NCEP ATP III and 2003 European LDL-C goals with rosuvastatin 10 mg compared with atorvastatin 20 mg (68.8% vs. 62.5%, p < 0.05; 68.0% vs. 63.3%, p < 0.05, respectively). High-density lipoprotein cholesterol was increased significantly with rosuvastatin 10 mg versus atorvastatin 20 mg (6.4% vs. 3.1%, p < 0.001). Lipid ratios and levels of apolipoprotein A-I also improved more with rosuvastatin 10 mg than with atorvastatin 20 mg. The use of rosuvastatin 10 mg was also cost-effective compared with atorvastatin 20 mg in both a US and a UK setting. Both treatments were well tolerated, with a similar incidence of adverse events (rosuvastatin 10 mg, 27.5%; atorvastatin 20 mg, 26.1%). No cases of rhabdomyolysis, liver, or renal insufficiency were recorded. Conclusion In high-risk patients with hypercholesterolemia, rosuvastatin 10 mg was more efficacious than atorvastatin 20 mg at reducing LDL-C, enabling LDL-C goal achievement and improving other lipid parameters. Both treatments were well tolerated.

Published
2006
Full Text
View/download PDF

3. Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry

Author

Cools, Frank, Johnson, Dana, Camm, Alan J., Bassand, Jean‐Pierre, Verheugt, Freek W.A., Yang, Shu, Tsiatis, Anastasios, Fitzmaurice, David A., Goldhaber, Samuel Z., Kayani, Gloria, Goto, Shinya, Haas, Sylvia, Misselwitz, Frank, Turpie, Alexander G.G., Fox, Keith A.A., Pieper, Karen S., and Kakkar, Ajay K.

Published
2021
Full Text
View/download PDF

7. Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD‐AF registry.

Author

Bassand, Jean‐Pierre, Virdone, Saverio, Camm, A. John, Fox, Keith A. A., Goldhaber, Samuel Z., Goto, Shinya, Haas, Sylvia, Hacke, Werner, Kayani, Gloria, Keltai, Matyas, Misselwitz, Frank, Pieper, Karen S., Turpie, Alexander G. G., Verheugt, Freek W. A., and Kakkar, Ajay K.

Subjects
*ATRIAL fibrillation, *PEOPLE with diabetes, *STROKE, *ANTICOAGULANTS
Abstract

Aims: This study aims to describe both management and prognosis of patients with diabetes mellitus (DM) and newly diagnosed atrial fibrillation (AF), overall as well as by antidiabetic treatment, and to assess the influence of oral anticoagulation (OAC) on outcomes by DM status. Methods: The study population comprised 52 010 newly diagnosed patients with AF, 11 542 DM and 40 468 non‐DM, enrolled in the GARFIELD‐AF registry. Follow‐up was truncated at 2 years after enrolment. Comparative effectiveness of OAC versus no OAC was assessed by DM status using a propensity score overlap weighting scheme and weights were applied to Cox models. Results: Patients with DM [39.3% oral antidiabetic drug (OAD), 13.4% insulin ± OAD, 47.2% on no antidiabetic drug] had higher risk profile, OAC use, and rates of clinical outcomes compared with patients without DM. OAC use was associated in patients without DM and patients with DM with lower risk of all‐cause mortality [hazard ratio 0.75 (0.69‐0.83), 0.74 (0.64‐0.86), respectively] and stroke/systemic embolism (SE) [0.69 (0.58‐0.83), 0.70 (0.53‐0.93), respectively]. The risk of major bleeding with OAC was similarly increased in patients without DM and those with DM [1.40 (1.14‐1.71), 1.37 (0.99‐1.89), respectively]. Patients with insulin‐requiring DM had a higher risk of all‐cause mortality and stroke/SE [1.91 (1.63‐2.24)], [1.57 (1.06‐2.35), respectively] compared with patients without DM, and experienced significant risk reductions of all‐cause mortality and stroke/SE with OAC [0.73 (0.53‐0.99); 0.50 (0.26‐0.97), respectively]. Conclusions: In both patients with DM and patients without DM with AF, OAC was associated with lower risk of all‐cause mortality and stroke/SE. Patients with insulin‐requiring DM derived significant benefit from OAC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

Author

Valgimigli, Marco, Bueno, Héctor, Byrne, Robert A., Collet, Jean-Philippe, Costa, Francesco, Jeppsson, Anders, Jüni, Peter, Kastrati, Adnan, Kolh, Philippe, Mauri, Laura, Montalescot, Gilles, Neumann, Franz-Josef, Petricevic, Mate, Roffi, Marco, Steg, Philippe Gabriel, Windecker, Stephan, Zamorano, Jose Luis, Levine, Glenn N., Badimon, Lina, Vranckx, Pascal, Agewall, Stefan, Andreotti, Felicita, Antman, Elliott, Barbato, Emanuele, Bassand, Jean-Pierre, Bugiardini, Raffaele, Cikirikcioglu, Mustafa, Cuisset, Thomas, De Bonis, Michele, Delgado, Victora, Fitzsimons, Donna, Gaemperli, Oliver, Galiè, Nazzareno, Gilard, Martine, Hamm, Christian W, Ibanez, Borja, Iung, Bernard, James, Stefan, Knuuti, Juhani, Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lip, Gregory, Piepoli, Massimo Francesco, Pierard, Luc, Schwerzmann, Markus, Sechtem, Udo, Simpson, Iain A, Uva, Miguel Sousa, Stabile, Eugenio, Storey, Robert F, Tendera, Michal, Van de Werf, Frans, Verheugt, Freek, and Aboyans, Victor

Published
2018
Full Text
View/download PDF

9. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide.

Author

Haas, Sylvia, Camm, John A., Harald, Darius, Steffel, Jan, Virdone, Saverio, Pieper, Karen, Brodmann, Marianne, Schellong, Sebastian, Misselwitz, Frank, Kayani, Gloria, Kakkar, Ajay K., Bassand, Jean-Pierre, Camm, A. John, Fitzmaurice, David A., Fox, Keith A. A., Gersh, Bernard J., Goldhaber, Samuel Z., Goto, Shinya, Hacke, Werner, and Mantovani, Lorenzo G.

Abstract

Background: The Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) is a worldwide non-interventional study of stroke prevention in patients with non-valvular AF. Methods and results: 52,080 patients with newly diagnosed AF were prospectively enrolled from 2010 to 2016. 4121 (7.9%) of these patients were recruited in DACH [Germany (n = 3567), Austria (n = 465) and Switzerland (n = 89) combined], and 47,959 patients were from 32 countries in other regions worldwide (ORW). Hypertension was most prevalent in DACH and ORW (85.3% and 75.6%, respectively). Diabetes, hypercholesterolaemia, carotid occlusive disease and vascular disease were more prevalent in DACH patients vs ORW (27.6%, 49.4%, 5.8% and 29.0% vs 21.7%, 40.9%, 2.8% and 24.5%). The use of non-vitamin K antagonist oral anticoagulants (NOACs) increased more in DACH over time. Management of vitamin K antagonists was suboptimal in DACH and ORW (time in therapeutic range of INR ≥ 65% in 44.6% and 44.4% of patients or ≥ 70% in 36.9% and 36.0% of patients, respectively). Adjusted rates of cardiovascular mortality and MI/ACS were higher in DACH while non-haemorrhagic stroke/systemic embolism was lower after 2-year follow-up. Conclusions: Similarities and dissimilarities in AF management and clinical outcomes are seen in DACH and ORW. The increased use of NOAC was associated with a mismatch of risk-adapted anticoagulation (over-and-undertreatment) in DACH. Suboptimal control of INR requires educational activities in both regional groups. Higher rates of cardiovascular death in DACH may reflect the higher risk profile of these patients and lower rates of non-haemorrhagic stroke could be associated with increased NOAC use. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

10. Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF.

Author

Camm, Alan John, Steffel, Jan, Virdone, Saverio, Bassand, Jean-Pierre, Fox, Keith A A, Goldhaber, Samuel Z, Goto, Shinya, Haas, Sylvia, Turpie, Alexander G G, Verheugt, Freek W A, Misselwitz, Frank, Herreros, Ramón Corbalán, Kayani, Gloria, Pieper, Karen S, and Kakkar, Ajay K

Subjects
ATRIAL fibrillation, PROPORTIONAL hazards models, PERIPHERAL vascular diseases, ORAL medication, CORONARY artery disease
Abstract

Aims: This study aimed to identify relationships in recently diagnosed atrial fibrillation (AF) patients with respect to anticoagulation status, use of guideline-directed medical therapy (GDMT) for comorbid cardiovascular conditions (co-GDMT), and clinical outcomes. The Global Anticoagulant Registry in the FIELD (GARFIELD)-AF is a prospective, international registry of patients with recently diagnosed non-valvular AF at risk of stroke (NCT01090362). Methods and results: Guideline-directed medical therapy was defined according to the European Society of Cardiology guidelines. This study explored co-GDMT use in patients enrolled in GARFIELD-AF (March 2013–August 2016) with CHA2DS2-VASc ≥ 2 (excluding sex) and ≥1 of five comorbidities—coronary artery disease, diabetes mellitus, heart failure, hypertension, and peripheral vascular disease (n = 23 165). Association between co-GDMT and outcome events was evaluated with Cox proportional hazards models, with stratification by all possible combinations of the five comorbidities. Most patients (73.8%) received oral anticoagulants (OACs) as recommended; 15.0% received no recommended co-GDMT, 40.4% received some, and 44.5% received all co-GDMT. At 2 years, comprehensive co-GDMT was associated with a lower risk of all-cause mortality [hazard ratio (HR) 0.89 (0.81–0.99)] and non-cardiovascular mortality [HR 0.85 (0.73–0.99)] compared with inadequate/no GDMT, but cardiovascular mortality was not significantly reduced. Treatment with OACs was beneficial for all-cause mortality and non-cardiovascular mortality, irrespective of co-GDMT use; only in patients receiving all co-GDMT was OAC associated with a lower risk of non-haemorrhagic stroke/systemic embolism. Conclusion: In this large prospective, international registry on AF, comprehensive co-GDMT was associated with a lower risk of mortality in patients with AF and CHA2DS2-VASc ≥ 2 (excluding sex); OAC therapy was associated with reduced all-cause mortality and non-cardiovascular mortality, irrespective of co-GDMT use. Clinical Trial Registration: Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362. Graphical abstract [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry.

Author

Mantovani, Lorenzo G., Cozzolino, Paolo, Ferrara, Pietro, Virdone, Saverio, Camm, A. John, Verheugt, Freek W. A., Bassand, Jean-Pierre, Turpie, Alexander G. G., Hacke, Werner, Kayani, Gloria, Goldhaber, Samuel Z., Goto, Shinya, Pieper, Karen S., Gersh, Bernard J., Fox, Keith A. A., Haas, Sylvia, van Eickels, Martin, and Kakkar, Ajay K.

Subjects
ATRIAL fibrillation diagnosis, ATRIAL fibrillation treatment, PATIENT aftercare, CONFIDENCE intervals, FISHER exact test, REGRESSION analysis, MEDICAL care use, DESCRIPTIVE statistics, HOSPITAL care, CHI-squared test, RESEARCH funding, STATISTICAL models, LONGITUDINAL method, OUTPATIENT services in hospitals, POISSON distribution
Abstract

The management of atrial fibrillation (AF), the most common sustained arrhythmia, impacts healthcare resource utilization (HCRU). This study aims to estimate global resource use in AF patients, using the GARFIELD-AF registry. A prospective cohort study was conducted to characterize HCRU in AF patients enrolled in sequential cohorts from 2012 to 2016 in 35 countries. Components of HCRU studied were hospital admissions, outpatient care visits, and diagnostic and interventional procedures occurring during follow-up. AF-related HCRU was reported as the percentage of patients demonstrating at least one event and was quantified as rate-per-patient-per-year (PPPY) over time. A total of 49,574 patients was analyzed, having an overall median follow-up of 719 days. Almost all patients (99.5%) had at least one outpatient care visit, while hospital admissions were the second most frequent medical contact, with similar proportions in North America (37.5%) and Europe (37.2%), and slightly higher in the other GARFIELD-AF countries (42.0%; namely Australia, Egypt, and South Africa). Asia and Latin America showed lower percentages of hospitalizations, outpatient care visits, and diagnostic and interventional procedures. Analyses of GARFIELD-AF highlighted the vast AF-related HCRU, underlying significant geographical differences in the type, quantity, and frequency of AF-related HCRU. These differences were likely attributable to health service availability and differing models of care. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

Author

Mehta, Shamir R, Tanguay, Jean-Francois, Eikelboom, John W, Jolly, Sanjit S, Joyner, Campbell D, Granger, Christopher B, Faxon, David P, Rupprecht, Hans-Jurgen, Budaj, Andrzej, Avezum, Alvaro, Widimsky, Petr, Steg, Philippe Gabriel, Bassand, Jean-Pierre, Montalescot, Gilles, Macaya, Carlos, Di Pasquale, Giuseppe, Niemela, Kari, Ajani, Andrew E, White, Harvey D, Chrolavicius, Susan, Gao, Peggy, Fox, Keith AA, and Yusuf, Salim

Published
2010
Full Text
View/download PDF

20. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group

Author

Rao, Sunil V., Eikelboom, John, Steg, Ph. Gabriel, Lincoff, A. Michael, Weintraub, William S., Bassand, Jean-Pierre, Rao, A. Koneti, Gibson, C. Michael, Petersen, John L., Mehran, Roxana, Manoukian, Steven V., Charnigo, Richard, Lee, Kerry L., Moscucci, Mauro, and Harrington, Robert A.

Published
2009
Full Text
View/download PDF

24. Supplement to: Rivaroxaban in patients with a recent acute coronary syndrome.

Author

Mega, Jessica L., Braunwald, Eugene, Wiviott, Stephen D., Bassand, Jean-Pierre, Bhatt, Deepak L., Bode, Christoph, Burton, Paul, Cohen, Marc, Cook-Bruns, Nancy, Fox, Keith A.A., Goto, Shinya, Murphy, Sabina A., Plotnikov, Alexei N., Schneider, David, Sun, Xiang, Verheugt, Freek W.A., and Gibson, Michael C.

Published
2012

30. Early versus delayed invasive intervention in acute coronary syndromes

Author

Mehta, Shamir R., Granger, Christopher B., Boden, William E., Steg, Philippe Gabriel, Bassand, Jean-Pierre, Faxon, David P., Afzal, Rizwan, Chrolavicius, Susan, Rupprecht, Hans-Jurgen, Avezum, Alvaro, Widimsky, Petr, Jolly, Sanjit S., Zhu, Jun, Col, Jacques, Natarajan, Madhu K., Horsman, Craig, Fox, Keith A.A., and Yusuf, Salim

Subjects
Angiography -- Usage, Angiography -- Health aspects, Heart attack -- Diagnosis, Heart attack -- Prevention, Cardiac patients -- Care and treatment
Abstract

A study was conducted to assess the effects of timing of routine invasive procedures in patients with acute coronary syndromes . Results showed that early intervention did not make a significant difference in the primary outcome but helped in preventing other related complications in high-risk patients.

Published
2009

31. Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF.

Author

Camm, Christian Fielder, Virdone, Saverio, Goto, Shinya, Bassand, Jean-Pierre, van Eickels, Martin, Haas, Sylvia, Gersh, Bernard J., Pieper, Karen, Fox, Keith A. A., Misselwitz, Frank, Turpie, Alexander G. G., Goldhaber, Samuel Z., Verheugt, Freek, Camm, John, Kayani, Gloria, Panchenko, Elizaveta, Seil Oh, Luciardi, Hector Lucas, Sawhney, Jitendra Pal Singh, and Connolly, Stuart J.

Published
2022
Full Text
View/download PDF

33. Impact of renal dysfunction on 1-year mortality after acute myocardial infarction

Author

Schiele, Francois, Legalery, Pierre, Didier, Katy, Meneveau, Nicolas, Seronde, Marie France, Caulfield, Fiona, Ducloux, Didier, Bechetoille, Patrick, Magnin, Dominique, Faivre, Rene, and Bassand, Jean-Pierre

Subjects
Heart attack -- Patient outcomes, Heart attack -- Research, Kidney failure -- Influence, Glomerular filtration rate -- Analysis, Mortality -- Risk factors, Health
Published
2006

36. Third universal definition of myocardial infarction

Author

Thygesen, Kristian, Alpert, Joseph S., Jaffe, Allan S., Simoons, Maarten L., Chaitman, Bernard R., White, Harvey D., Thygesen, Kristian, Alpert, Joseph S., White, Harvey D., Jaffe, Allan S., Katus, Hugo A., Apple, Fred S., Lindahl, Bertil, Morrow, David A., Chaitman, Bernard R., Clemmensen, Peter M., Johanson, Per, Hod, Hanoch, Underwood, Richard, Bax, Jeroen J., Bonow, Robert O., Pinto, Fausto, Gibbons, Raymond J., Fox, Keith A., Atar, Dan, Newby, L. Kristin, Galvani, Marcello, Hamm, Christian W., Uretsky, Barry F., Gabriel Steg, Ph., Wijns, William, Bassand, Jean-Pierre, Menasché, Phillippe, Ravkilde, Jan, Ohman, E. Magnus, Antman, Elliott M., Wallentin, Lars C., Armstrong, Paul W., Simoons, Maarten L., Januzzi, James L., Nieminen, Markku S., Gheorghiade, Mihai, Filippatos, Gerasimos, Luepker, Russell V., Fortmann, Stephen P., Rosamond, Wayne D., Levy, Dan, Wood, David, Smith, Sidney C., Hu, Dayi, Lopez-Sendon, José-Luis, Robertson, Rose Marie, Weaver, Douglas, Tendera, Michal, Bove, Alfred A., Parkhomenko, Alexander N., Vasilieva, Elena J., Mendis, Shanti, Bax, Jeroen J., Baumgartner, Helmut, Ceconi, Claudio, Dean, Veronica, Deaton, Christi, Fagard, Robert, Funck-Brentano, Christian, Hasdai, David, Hoes, Arno, Kirchhof, Paulus, Knuuti, Juhani, Kolh, Philippe, McDonagh, Theresa, Moulin, Cyril, Popescu, Bogdan A., Reiner, Željko, Sechtem, Udo, Sirnes, Per Anton, Tendera, Michal, Torbicki, Adam, Vahanian, Alec, Windecker, Stephan, Morais, Joao, Aguiar, Carlos, Almahmeed, Wael, Arnar, David O., Barili, Fabio, Bloch, Kenneth D., Bolger, Ann F., Bøtker, Hans Erik, Bozkurt, Biykem, Bugiardini, Raffaele, Cannon, Christopher, de Lemos, James, Eberli, Franz R., Escobar, Edgardo, Hlatky, Mark, James, Stefan, Kern, Karl B., Moliterno, David J., Mueller, Christian, Neskovic, Aleksandar N., Pieske, Burkert Mathias, Schulman, Steven P., Storey, Robert F., Taubert, Kathryn A., Vranckx, Pascal, and Wagner, Daniel R.

Published
2012
Full Text
View/download PDF

38. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

Author

Mega, Jessica L., Braunwald, Eugene, Wiviott, Stephen D., Bassand, Jean-Pierre, Bhatt, Deepak L., Bode, Christoph, Burton, Paul, Cohen, Marc, Cook-Bruns, Nancy, Fox, Keith A.A., Goto, Shinya, Murphy, Sabina A., Plotnikov, Alexei N., Schneider, David, Sun, Xiang, Verheugt, Freek W.A., and Gibson, Michael C.

Published
2012
Full Text
View/download PDF

39. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

Author

Hamm, Christian W., Bassand, Jean-Pierre, Agewall, Stefan, Bax, Jeroen, Boersma, Eric, Bueno, Hector, Caso, Pio, Dudek, Dariusz, Gielen, Stephan, Huber, Kurt, Ohman, Magnus, Petrie, Mark C., Sonntag, Frank, Uva, Miguel Sousa, Storey, Robert F., Wijns, William, Zahger, Doron, Bax, Jeroen J., Auricchio, Angelo, Baumgartner, Helmut, Ceconi, Claudio, Dean, Veronica, Deaton, Christi, Fagard, Robert, Funck-Brentano, Christian, Hasdai, David, Hoes, Arno, Knuuti, Juhani, Kolh, Philippe, McDonagh, Theresa, Moulin, Cyril, Poldermans, Don, Popescu, Bogdan A., Reiner, Željko, Sechtem, Udo, Sirnes, Per Anton, Torbicki, Adam, Vahanian, Alec, Windecker, Stephan, Windecker, Stephan, Achenbach, Stephan, Badimon, Lina, Bertrand, Michel, Bøtker, Hans Erik, Collet, Jean-Philippe, Crea, Filippo, Danchin, Nicolas, Falk, Erling, Goudevenos, John, Gulba, Dietrich, Hambrecht, Rainer, Herrmann, Joerg, Kastrati, Adnan, Kjeldsen, Keld, Kristensen, Steen Dalby, Lancellotti, Patrizio, Mehilli, Julinda, Merkely, Béla, Montalescot, Gilles, Neumann, Franz-Josef, Neyses, Ludwig, Perk, Joep, Roffi, Marco, Romeo, Francesco, Ruda, Mikhail, Swahn, Eva, Valgimigli, Marco, Vrints, Christiaan JM, and Widimsky, Petr

Published
2011
Full Text
View/download PDF

41. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology

Author

Steg, Philippe Gabriel, Huber, Kurt, Andreotti, Felicita, Arnesen, Harald, Atar, Dan, Badimon, Lina, Bassand, Jean-Pierre, De Caterina, Raffaele, Eikelboom, John A., Gulba, Dietrich, Hamon, Martial, Helft, Gérard, Fox, Keith A.A., Kristensen, Steen D., Rao, Sunil V., Verheugt, Freek W.A., Widimský, Petr, Zeymer, Uwe, and Collet, Jean-Philippe

Published
2011
Full Text
View/download PDF

48. Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation – results from the GARFIELD-AF registry.

Author

Pope, Marita Knudsen, Atar, Dan, Svilaas, Arne, Hole, Torstein, Nielsen, Jørn Dalsgaard, Hintze, Ulrik, Crisby, Milita, Raatikainen, Pekka, Airaksinen, K. E. Juhani, Virdone, Saverio, Pieper, Karen, Kayani, Gloria, Le Heuzey, Jean-Yves, Steffel, Jan, Stepinska, Janina, Bassand, Jean-Pierre, and Camm, A. John

Subjects
ATRIAL fibrillation, TREATMENT effectiveness, STROKE, ORAL medication, MORTALITY
Abstract

The objective was to evaluate the clinical characteristics, management and two-year outcomes of patients with newly diagnosed non-valvular atrial fibrillation at risk for stroke in Nordic countries. We examined the baseline characteristics, antithrombotic treatment, and two-year clinical outcomes of patients from four Nordic countries. A total of 52,080 patients were enrolled in the GARFIELD-AF. Out of 29,908 European patients, 2,396 were recruited from Nordic countries. The use of oral anticoagulants, alone or in combination with antiplatelet (AP), was higher in Nordic patients in all CHA2DS2-VASc categories: 0–1 (72.8% vs 60.3%), 2–3 (78.7% vs 72.9%) and ≥4 (79.2% vs 74.1%). In Nordic patients, NOAC ± AP was more frequently prescribed (32.0% vs 27.7%) and AP monotherapy was less often prescribed (10.4% vs 18.2%) when compared with Non-Nordic European patients. The rates (per 100 patient years) of all-cause mortality and non-haemorrhagic stroke/systemic embolism (SE) were similar in Nordic and Non-Nordic European patients [3.63 (3.11–4.23) vs 4.08 (3.91–4.26), p value =.147] and [0.98 (0.73–1.32) vs 1.02 (0.93–1.11), p value =.819], while major bleeding was significantly higher [1.66 (1.32–2.09) vs 1.01 (0.93–1.10), p value <.001]. Nordic patients had significantly higher major bleeding than Non-Nordic-European patients. In contrast, rates of all-cause mortality and non-haemorrhagic stroke/SE were comparable. Unique identifier: NCT01090362. URL: . Nordic countries had significantly higher major bleeding than Non-Nordic-European countries. Rates of mortality and non-haemorrhagic stroke/SE were similar. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)

Author

Torbicki, Adam, Perrier, Arnaud, Konstantinides, Stavros, Agnelli, Giancarlo, Galiè, Nazzareno, Pruszczyk, Piotr, Bengel, Frank, Brady, Adrian J.B., Ferreira, Daniel, Janssens, Uwe, Klepetko, Walter, Mayer, Eckhard, Remy-Jardin, Martine, Bassand, Jean-Pierre, Vahanian, Alec, Camm, John, De Caterina, Raffaele, Dean, Veronica, Dickstein, Kenneth, Filippatos, Gerasimos, Funck-Brentano, Christian, Hellemans, Irene, Kristensen, Steen Dalby, McGregor, Keith, Sechtem, Udo, Silber, Sigmund, Tendera, Michal, Widimsky, Petr, Zamorano, Jose Luis, Zamorano, Jose-Luis, Andreotti, Felicita, Ascherman, Michael, Athanassopoulos, George, De Sutter, Johan, Fitzmaurice, David, Forster, Tamas, Heras, Magda, Jondeau, Guillaume, Kjeldsen, Keld, Knuuti, Juhani, Lang, Irene, Lenzen, Mattie, Lopez-Sendon, Jose, Nihoyannopoulos, Petros, Isla, Leopoldo Perez, Schwehr, Udo, Torraca, Lucia, and Vachiery, Jean-Luc

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results